ALK-B 📈 ALK-Abelló - Overview

ALK-Abelló A/S is a leading allergy solutions company with a significant presence in Europe, North America, and international markets. The company's product portfolio is diverse, featuring a range of allergy immunotherapy treatments, including GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK, which cater to the treatment of allergic rhinitis and allergic asthma. These products are available in various forms, such as injections, sublingual drops, and tablets, allowing for flexible treatment options for patients suffering from allergies to grass, ragweed, house dust mite, Japanese cedar, tree, and food.

The company's approach to allergy treatment extends beyond pharmaceutical products, with a focus on providing comprehensive solutions that support patients throughout their treatment journey. This includes a digital ecosystem, a platform designed to connect and engage with allergy sufferers, offering tools, guidance, and relief, as well as e-commerce offerings that facilitate access to allergy immunotherapy treatments. By leveraging technology, ALK-Abelló A/S aims to streamline the path to treatment, making it more accessible and convenient for patients to manage their allergies.

ALK-Abelló A/S also offers diagnostic allergy solutions, utilizing skin prick tests or blood tests to identify specific allergies. Furthermore, the company provides emergency treatment options, including intra-muscular injections of adrenaline, which are crucial for treating acute, life-threatening allergic reactions, such as anaphylaxis. The company's commitment to collaboration is evident in its partnership with Torii Pharmaceutical Co., Ltd., which focuses on the development, marketing, and distribution of an allergy immunotherapy tablet for the treatment of grass pollen allergy.

With a rich history dating back to 1923, ALK-Abelló A/S is headquartered in Horsholm, Denmark, and has established itself as a prominent player in the biotechnology industry, specifically within the biotechnology sub-industry. The company's common stock is listed under the ISIN code DK0061802139, and its web presence can be found at https://www.alk.net, providing a central hub for information on its products, services, and initiatives.